Table 1.
CsA | wks 2–12 | wks 28–104 | ||||
---|---|---|---|---|---|---|
n* | Dose (mg/kg) |
AUC (ng*hr/mL/mg/kg) |
n* | Dose (mg/kg) |
AUC (ng*hr/mL/mg/kg) |
|
nonHIV tx† | 55 | 4 | 7000–9000 | 55 | 2 | 4500–6000 |
+PI | 34 | 0.36 | 5759 [3325–8045] | 16 | 0.34 | 5603 [3867–6658] |
+EFV | 18 | 4.03 | 862 [744–1131] | 4 | 1.74 | 1201 [992–1422] |
+NVP | 18 | 2.21 | 1945 [1585–3277] | 21 | 1.47 | 1905 [1486–2557] |
+PI +EFV | 3 | 4.03 | 10290 [8887–13778] | N/A | N/A | N/A |
+PI +NVP | 10 | 0.50 | 6718 [3933–7941] | 10 | 0.63 | 5007 [3281–9168] |
TAC | wks 2–12 | wks 28–104 | ||||
---|---|---|---|---|---|---|
n* | Dose (mg/kg) |
AUC (ng*hr/mL/mg/kg) |
n* | Dose (mg/kg) |
AUC (ng*hr/mL/mg/kg) |
|
nonHIV tx† | 44 | 0.10 | 2000–5000 | 44 | 0.15 | 2000–5000 |
+PI | 8 | 0.007 | 24996 [18205–41601] | 3 | 0.003 | 34653 [17208–42250] |
+EFV | 3 | 0.058 | 2170 [936–3261] | 4 | 0.046 | 1911 [1423–3071] |
+NVP | 5 | 0.021 | 3644 [3115–5157] | 6 | 0.029 | 4220 [2703–6229] |
number of PK studies
from ref [18].